Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 201–300 of 1,004
Baek, M. L., Lee, J., Pendleton, K. E., Berner, M. J., Goff, E. B., Tan, L., Martinez, S. A., Mahmud, I., Wang, T., Meyer, M. D., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02596-8 · Cited by 94
“Recently, combination chemotherapy has been augmented by the addition of PDL1 inhibition with a marginal, but statistically significant, increase in efficacy [6].”
BackgroundENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer
Wang, S., Böhnert, V., Joseph, A. J., Sudaryo, V., Skariah, G. M., Swinderman, J. T., Yu, F. B., Subramanyam, V., Wolf, D. M., Lyu, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313693120 · Cited by 105
“…T - lymphocyte associated protein 4 (CTLA - 4) offers curative immunotherapy for some patients with otherwise terminal cancer diagnoses — however, only a minority of patients respond to immune checkpoint blockade (ICB) therapy and many cancer types remain inaccessible by this treatment (1–6).”
BackgroundVillacampa, G. J., Navarro, V., Matikas, A., Ribeiro, J. M., Schettini, F., Tolosa, P., Martínez‐Sáez, O., Sánchez-Bayona, R., Ferrero-Cafiero, J. M., Salvador, F., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3456 · Cited by 101
Badve, S., Penault-Llorca, F. M., Reis-Filho, J. S., Deurloo, R., Siziopikou, K. P., D’Arrigo, C., & Viale, G. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab121 · Cited by 98
Spring, L. M., Tolaney, S. M., Fell, G. G., Bossuyt, V., Abelman, R. O., Wu, B., Maheswaran, S., Trippa, L., Comander, A. H., Mulvey, T. M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.018 · Cited by 100
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 102
Breast Cancer Heterogeneity and Response to Novel Therapeutics
Baliu‐Piqué, M., Pandiella, A., & Ocaña, A. (2020) · Cancers · doi:10.3390/cancers12113271 · Cited by 97
The immunomodulatory effects of endocrine therapy in breast cancer
Huang, H., Zhou, J., Chen, H., Li, J., Zhang, C., Jiang, X., & Ni, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01788-4 · Cited by 95
Corti, C., Venetis, K., Sajjadi, E., Zattoni, L., Curigliano, G., & Fusco, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2054326 · Cited by 96
“001), compared with chemotherapy alone, at the median follow-up of 39 months in the phase III KEYNOTE-522 clinical trial [21].”
BackgroundRibeiro, R., Carvalho, M. J., Gonçalves, J., & Moreira, J. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903065 · Cited by 90
Current and future immunotherapy for breast cancer
Heater, N. K., Warrior, S., & Lu, J. M. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01649-z · Cited by 115
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 92
Loi, S., Salgado, R., Adams, S., Pruneri, G., Francis, P. A., Lacroix‐Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-021-00362-1 · Cited by 94
Doxorubicin prodrug-based nanomedicines for the treatment of cancer
Zhao, H., Yu, J., Zhang, R., Chen, P., Jiang, H., & Yu, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115612 · Cited by 86
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 87
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
Portuguese, A. J., Tykodi, S. S., Blosser, C. D., Gooley, T., Thompson, J. A., & Hall, E. T. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7009 · Cited by 90
Role of Immunotherapy in Breast Cancer
Jacob, S. L., Huppert, L. A., & Rugo, H. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00483 · Cited by 85
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer
Liang, W., Liu, H., Zeng, Z., Liang, Z., Xie, H., Li, W., Xiong, L., Liu, Z., Chen, M., Jie, H., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0814 · Cited by 90
“Emerging clinical evidence has demonstrated that immune checkpoint inhibitors (ICI) have durable antitumor activity in multiple cancer types (3, 4).”
Fujiwara, Y., Horita, N., Adib, E., Zhou, S., Nassar, A. H., Asad, Z. U. A., Cortellini, A., & Naqash, A. R. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00524-7 · Cited by 95
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
Breast Cancer Statistics in Korea, 2019
Choi, J. E., Kim, Z., Park, C. S., Park, E. H., Lee, S. B., Lee, S. K., Choi, Y. J., Han, J., Jung, K., Kim, H. J., et al. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e27 · Cited by 87
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Yam, C., Yen, E.-Y., Chang, J. T., Bassett, R. L., Alatrash, G., Garber, H. R., Huo, L., Yang, F., Philips, A. V., Ding, Q., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0144 · Cited by 78
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 84
Ji, P., Gong, Y., Jin, M., Wu, H., Guo, L., Pei, Y., Chai, W.-J., Jiang, Y., Liu, Y., Ma, X.-Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl8247 · Cited by 97
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
Choi, H., Jeong, S., Simó, C., Bakenecker, A. C., Llop, J., Lee, H. S., Kim, T., Kwak, C. H., Koh, G. Y., Sánchez, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54293-z · Cited by 92
Yoder, R., Kimler, B. F., Staley, J. M., Schwensen, K., Wang, Y. Y., Finke, K., O’Dea, A. P., Nye, L. E., Elia, M., Crane, G. J., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00448-4 · Cited by 89
Soliman, H. H., Hogue, D., Han, H. S., Mooney, B. P., Costa, R. L. B., Lee, M. C., Niell, B. L., Williams, A. R., Chau, A., Falcon, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02210-0 · Cited by 129
Nederlof, I., Isaeva, O. I., de Graaf, M., Gielen, R., Bakker, N. A. M., Rolfes, A. L., Garner, H., Boeckx, B., Traets, J. J. H., Mandjes, I. A. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03249-3 · Cited by 94
“The addition of anti-PD-(L)1 to neoadjuvant chemotherapy has changed the treatment landscape for patients with early (stage II–III) triple-negative breast cancer (TNBC) 1 ; however, all trials evaluating the efficacy of anti-PD-(L)1 in TNBC combined it with chemotherapy 1–4 .”
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 76
Metzger, O., Stover, D. G., Asad, S., Ansell, P. J., Watson, M. A., Loibl, S., Geyer, C. E., Bae, J., Collier, K. A., Cherian, M. A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7310 · Cited by 87
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Spring, L. M., Bar, Y., & Isakoff, S. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7016 · Cited by 91
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76
“The introduction of immune checkpoint inhibitors (ICIs) in the neoadjuvant setting for triple negative BC requests to improve the management of cardiovascular toxicity in BC patients [76]: cardiotoxicity is a very rare adverse event of ICIs, affecting up to 1% of patients, and myocarditis is the most common presentati…”
BackgroundUnderstanding PD-L1 Testing in Breast Cancer: A Practical Approach
Erber, R., & Hartmann, A. (2020) · Breast Care · doi:10.1159/000510812 · Cited by 88
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
Petruk, N., Tuominen, S., Åkerfelt, M., Mattsson, J., Sandholm, J. A., Nees, M., Yegutkin, G. G., Jukkola‐Vuorinen, A., Tuomela, J. M., & Selander, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-85379-z · Cited by 89
Keelan, S., Flanagan, M., & Hill, A. D. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.622621 · Cited by 82
Wang, B., Sun, T., Zhao, Y., Wang, S., Zhang, J., Wang, Z., Teng, Y.-E., Cai, L., Yan, M., Wang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31704-7 · Cited by 81
Toxicity in the era of immune checkpoint inhibitor therapy
Keam, S., Turner, N., Kugeratski, F. G., Rico, R., Colunga-Minutti, J., Poojary, R., Alekseev, S., Patel, A. B., Li, Y. J., Sheshadri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447021 · Cited by 92
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 78
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
Pellegrino, B., Hlavata, Z., Migali, C., Silva, P. D., Aiello, M. M., Willard-Gallo, K. E., Musolino, A., & Solinas, C. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00525-7 · Cited by 86
Taylor, B. C., Sun, X., Ericsson, P. I. G., Sanchez, V. M., Sanders, M. E., Wescott, E. C., Opalenik, S. R., Hanna, A., Chou, S.-T., Kaer, L. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0519 · Cited by 81
“To investigate the expression on the outcome of ICI treatment, the abundance of HLA-A/B/C tumor regions in pretherapy biopsy samples from the clinical trial of carboplatin atezolizumab in metastatic TNBC was evaluated.”
InfluentialXu, L., Saunders, K., Huang, S.-P., Knútsdóttir, H., Martinez-Algarin, K., Terrazas, I., Chen, K., McArthur, H., Maués, J., Hodgdon, C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101511 · Cited by 117
Montagna, G., Gupta, H. V., Hannum, M., Tan, K. S., Lee, J., Scarpa, J. R., Plitas, G., Irie, T., McCormick, P. J., Fischer, G. W., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.021 · Cited by 79
Immunotherapy in Triple-Negative Breast Cancer
Emens, L. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000497 · Cited by 81
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 87
Drug resistance in breast cancer: Mechanisms and strategies for management
Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 90
Sanchez, K. G., Kim, I., Chun, B., Pucilowska, J., Redmond, W. L., Urba, W. J., Martel, M., Wu, Y., Campbell, M. B., Sun, Z., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01378-4 · Cited by 119
Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls
Cimino‐Mathews, A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00697-3 · Cited by 82
Foldi, J., Silber, A. L. M., Reisenbichler, E., Singh, K., Fischbach, N. A., Persico, J., Adelson, K. B., Katoch, A., Horowitz, N. R., Lannin, D. R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00219-7 · Cited by 72
Galsky, M. D., Hoimes, C. J., Necchi, A., Shore, N. D., Witjes, J. A., Steinberg, G. D., Bedke, J., Nishiyama, H., Fang, X., Kataria, R. S., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0273 · Cited by 77
Update on prognostic and predictive biomarkers of breast cancer
Hou, Y., Peng, Y. S., & Li, Z. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.06.015 · Cited by 77
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 78
Shin, J. M., Lee, C., Son, S., Kim, C. H., Lee, J. A., Ko, H., Shin, S., Song, S. H., Park, S., Bae, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202103245 · Cited by 68
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Chen, Z., Liu, Y., Lyu, M., Chan, C. H., Sun, M., Yang, X., Qiao, S., Chen, Z., Yu, S., Ren, M., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01359-0 · Cited by 92
“On the other hand, the FDA has approved pembrolizumab in combination with chemotherapy for high-risk early-stage TNBC patients, irrespective of tumor PD-L1 expression, based on the promising results from the KEYNOTE-522 trial [60].”
Hamada, N., Maeda, A., Takase‐Minegishi, K., Kirino, Y., Sugiyama, Y., Namkoong, H., Horita, N., Yoshimi, R., Nakajima, H., & YCU irAE Working Group (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803410 · Cited by 80
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 81
“The KEYNOTE 522 study (8) suggested that, in TNBC patients, the addition of PD-1 inhibitors on the basis of TP-AC in neoadjuvant therapy significantly increased the pCR rate, and the continued use of PD-1 inhibitors after surgery further improved the event-free survival (EFS) ( Table 3 ).”
Wang, X., Semba, T., Manyam, G. C., Wang, J., Shao, S. H., Bertucci, F., Finetti, P., Krishnamurthy, S., Phi, L. T. H., Pearson, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn7983 · Cited by 74
Immunotherapy Treatment for Triple Negative Breast Cancer
Berger, E. R., Park, T. S., Saridakis, A., Golshan, M. A., Greenup, R. A., & Ahuja, N. (2021) · Pharmaceuticals · doi:10.3390/ph14080763 · Cited by 79
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
Abad, M. N., Fariñas, S. C., de Mena, M. L., Torres‐Martínez, S., González, C. G., García, J. Á., Iranzo, V., & Camps, C. (2022) · Cancers · doi:10.3390/cancers14020307 · Cited by 71
Regulatory implications of ctDNA in immuno-oncology for solid tumors
Vellanki, P. J., Ghosh, S., Pathak, A., Fusco, M. J., Bloomquist, E. W., Tang, S. W., Singh, H., Philip, R., Pazdur, R., & Beaver, J. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005344 · Cited by 81
Zhou, B., Wang, L., Yin, H., Wu, T., Ren, T., Peng, C., Li, D.-X., Shi, H., Sun, L., Zhao, C.-K., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103684 · Cited by 77
Singh, S., Lee, N., Pedroza, D. A., Bado, I., Hamor, C., Zhang, L., Aguirre, S., Hu, J., Shen, Y., Xu, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3714 · Cited by 71
Shang, C., & Xu, D. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027640 · Cited by 103
Ding, S., Qiao, N., Zhu, Q., Tong, Y., Wang, S., Chen, X., Tian, Q., Xiao, Y., & Shen, K. (2023) · 癌症:英文版 · doi:10.1002/cac2.12429 · Cited by 74
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 70
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach
Sheng, J. Y.-S., Santa-Maria, C. A., Mangini, N. S., Norman, H., Couzi, R. J., Nunes, R., Wilkinson, M. J., Visvanathan, K., Connolly, R. M., Torres, E. T. R., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00364 · Cited by 72
Soliman, H. H., Hogue, D., Han, H. S., Mooney, B. P., da Costa, R. A., Lee, M. C., Niell, B. L., Williams, A. R., Chau, A., Falcon, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3105 · Cited by 75
Torrisi, R., Marrazzo, E., Agostinetto, E., Sanctis, R. D., Losurdo, A., Masci, G., Tinterri, C., & Santoro, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103280 · Cited by 65
Lee, K., Lin, C.-C. A., Servetto, A., Bae, J., Kandagatla, V., Ye, D., Kim, G. M., Sudhan, D. R., Mendiratta, S., Ericsson, P. I. G., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0826 · Cited by 74
Domergue, C., Martin, E., Lemarié, C., Jézéquel, P., Frenel, J., Augereau, P., Campone, M., & Patsouris, A. (2022) · Cancers · doi:10.3390/cancers14102509 · Cited by 67
“More recently, PARP inhibitors in patients with a germline mutation of BRCA1/2 [4,5] and immunotherapy [6] have shown efficacy in early settings.”
BackgroundWang, X., Collet, L., Rediti, M., Debien, V., Caluwé, A. D., Venet, D., Romano, E., Rothé, F., Sotiriou, C. P., & Buisseret, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030953 · Cited by 76
“Interestingly, PD-L1 expression on pre-therapeutic BC biopsies did not predict pCR in the neoadjuvant IMpassion 031 and KEYNOTE 522 trials [1,6].”
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
Han, H. S., Vikas, P., Costa, R. L. B., Jahan, N., Taye, A., & Stringer-Reasor, E. M. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390464 · Cited by 76
Terada, M., Ito, A., Kikawa, Y., Koizumi, K., Naito, Y., Shimoi, T., Ishihara, M., Yamanaka, T., Ozaki, Y., Hara, F., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01505-x · Cited by 73
“…we list all background questions (BQs), clinical questions (CQs) and future research questions (FRQs), with addition of details on important CQs derived from the POTENT [5], monarchE [6], RESPECT [7], KEYNOTE-522 [8], MONALEESA-7 [9], SELECT BC [10], DESTINY-Breast03 [11], and OlympiA [12] trials.”
BackgroundShang, X., Xie, Y., Yu, J., Zhang, C., Zhao, G., Liang, F., Liu, L., Zhang, W., Li, R., Yu, W., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.008 · Cited by 74
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., & Cortés, J. (2020) · BioDrugs · doi:10.1007/s40259-020-00436-9 · Cited by 69
Immunotherapy Approaches for Breast Cancer Patients in 2023
Emens, L. A., & Loi, S. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041332 · Cited by 70
Lu, B., Natarajan, E., Raghavendran, H. R. B., & Markandan, U. D. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221145246 · Cited by 80
“Molecular subtypes help reveal the occurrence and development of TNBC.”
BackgroundInfluentialLate-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Durbin, S., Zubiri, L., Perlman, K., Wu, C., Lim, T., Grealish, K., Hathaway, N., LoPiccolo, J., Wang, M., Falade, A. S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2668 · Cited by 81
Current status of immunotherapy for advanced gastric cancer
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa202 · Cited by 67
Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer
Jaiswal, A., Murakami, K., Elia, A., Shibahara, Y., Done, S. J., Wood, S. A., Donato, N. J., Ohashi, P. S., & Reedijk, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101592118 · Cited by 67
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 76
Ademuyiwa, F. O., Gao, F., Street, C., Chen, I., Northfelt, D., Wesolowski, R., Arora, M., Brufsky, A., Dees, E. C., Santa-Maria, C. A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00500-3 · Cited by 69
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Trimboli, R. M., Rossi, P. G., Battisti, N. M. L., Cozzi, A., Magni, V., Zanardo, M., & Sardanelli, F. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00905-3 · Cited by 66
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Bertucci, F., Boudin, L., Finetti, P., Berckelaer, C. V., van Dam, P. A., Dirix, L. Y., Viens, P., Gonçalvès, A., Ueno, N. T., Laere, S. V., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929724 · Cited by 64
Lee, Y. J., Kim, J. Y., Jeon, S. H., Nam, H., Jung, J. H., Jeon, M., Kim, E.-S., Bae, S. J., Ahn, J., Yoo, T.-K., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8390 · Cited by 66
Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment
Adrada, B. E., Moseley, T. W., Kapoor, M. M., Scoggins, M. E., Patel, M. M., Perez, F., Nia, E. S., Khazai, L., Arribas, E. M., Rauch, G. M., et al. (2023) · Radiographics · doi:10.1148/rg.230034 · Cited by 88
Carter, J. M., Polley, M. C., Leon-Ferre, R. A., Sinnwell, J. P., Thompson, K. J., Wang, X., Ma, Y., Zahrieh, D., Kachergus, J. M., Solanki, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0343 · Cited by 61
Locally advanced breast cancer
Aebi, S. P., Karlsson, P., & Wapnir, I. (2021) · The Breast · doi:10.1016/j.breast.2021.12.011 · Cited by 60
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020636 · Cited by 64
Su, G.-H., Xiao, Y., Jiang, L., Zheng, R., Wang, H., Chen, Y., Gu, Y., You, C., & Shao, Z.-M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03688-x · Cited by 69
Hu, X., Yang, P., Chen, S., Wei, G., Yuan, L., Yang, Z., Gong, L., He, L., Yang, L., Peng, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01639-y · Cited by 69
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 64
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer
Furlanetto, J., & Loibl, S. (2020) · Breast Care · doi:10.1159/000508759 · Cited by 73
Miglietta, F., Dieci, M. V., Griguolo, G., & Guarneri, V. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102222 · Cited by 60
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies
Zhao, N., & Rosen, J. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.010 · Cited by 62
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 72
Epigenetic Therapies and Biomarkers in Breast Cancer
Brown, L. J., Achinger-Kawecka, J., Portman, N., Clark, S. J., Stirzaker, C., & Lim, E. (2022) · Cancers · doi:10.3390/cancers14030474 · Cited by 68
Li, Q., Zhong, X., Yao, W., Yu, J., Wang, C., Li, Z., Lai, S., Qu, F., Fu, X., Huang, X., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101753 · Cited by 65
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.